Replies to post #152243 on Biotech Values

[DewDiligence]

ABT…no SOC treatment arm. Approvable?

Yes, IMO. I noted in #msg-81414058 that the SAPHIRE-III and -IV studies are +/- ribavirin and lack a traditional control arm, while the SAPHIRE-I and -II studies have placebo control arms (with deferred treatment on non-placebo regimens).

It’s the totality of ABT’s phase-3 program in genotype-1 HCV that you should be critiquing, not one or two trials in isolation.

p.s. The trial you linked to is SAPHIRE-I.